Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Ocular Histoplasmosis Syndrome

In brief

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.

Key facts

Study ID

NCT00955630

Run by

Retina Associates of Kentucky

People needed

20

Starts

2009-08-01

Last updated by the study team

2009-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 18 or over
• active choroidal neovascularization secondary to ocular histoplasmosis
• Visual acuity between 20/25 and 20/400

You may not qualify if…

• pregnancy or intent to become pregnant within the next 12 months
• nursing an infant
• premenopausal women not using contraception
• prior treatment with subfoveal thermal laser
• allergy to sodium fluorescein simultaneous participation in another investigation or trial

Where it is running

• Retina Associates of Kentucky — Lexington, Kentucky, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.